Abstract-TRK-100 (0.03, 0.1 and 0.3 mg/kg, p.o.), a chemically stable analogue of prostacyclin, dose-dependently prevented blood coagulation and glomerular fibrin deposition which were enhanced by 4 hr infusion of endotoxin (100 mg/kg) in rats. In addition, TRK-100 suppressed the generation of endotoxin-induced tissue thromboplastin like activity in cultured human endothelial cells.
Vascular endothelial
cells are considered to be anti-thrombogenic, while they par ticipate in coagulation reactions when in jured by various kinds of stimuli (1) . Endo toxin is one of such injuring stimuli and known to cause shock and disseminated intra vascular coagulation (DIC) in human and experimental animals (2, 3) . The mechanism by which endotoxin induces DIC has not been fully elucidated yet. There are a number of reports suggesting the involvement of tissue factor. It is a procoagulant activity generated from injured endothelial cells, which might promote coagulation as a trigger in the onset of DIC (4, 5) .
PG12 is known to possess diverse biological activities besides antiplatelet activity, but its chemical instability has restricted the detailed elucidation of these activities. TRK-100 is a stable analogue of PG12, and its actions are shown to mimic well the original PG12 (6) (7) (8) . We studied the effect of TRK-100 on the endotoxin-induced blood coagulation and glomerular fibrin deposit in rats and the generation of tissue factor in cultured human endothelial cells. In addition, we compared the effects of TRK-100 with those of gabexate mesilate (GM) (Ono Pharmaceutical Co., Osaka, Japan), an anticoagulant with serine protease inhibitory activity (9) .
Male Wistar rats weighing 191 to 225 g were used for the experiments.
Rats were infused endotoxin (Lipopolysaccharide B , E.
coli 055:B5, Difco, U.S.A.) at a dose of 100 mg/kg over 4 hr under urethane anesthesia (10) . TRK-100, synthesized in the laboratory of Toray Industries, was administered p.o. at doses ranging from 0.03 to 0.3 mg/kg 30 min before and GM was injected i.p. at 10 mg/ kg immediately before the infusion of endotoxin, respectively. In the normal group, the rats received i.v. the same volume of saline over 4 hr as the endotoxin infusion. Im mediately after the infusion, the blood was collected from the abdominal aorta, and then,' both kidneys were removed and fixed in a 10% buffered neutral formalin solution. Ac tivated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen and fibrin degradation product (FDP), fibrinogen level and platelet count were measured to study the effect of endotoxin on blood parameters. FDP was determined by the latex aggregation reaction using the FDPL® test (Teikokuzoki Pharmaceutical Co., Tokyo, Japan). APTT and PT were determined using clinical assay kits (Toa lyo Denshi, Kobe, Japan).
Fibri nogen was also determined by measuring the clotting time to form fibrin clots from fibrino gen by addition of excess thrombin using the same kit. The number of platelets was counted with an automatic platelet counter (Toa Iyo Denshi, PL-100).
The ratio of fibrin de positing glomeruli to 100 glomeruli observed was calculated for individual kidneys stained with phosphotungstic acid-hematoxylin. The data was represented as % of glomerulus fibrin deposit rate (GFD).
Human endothelial cells were obtained from the umbilical cord vein as described by Jaffe et al. (11) . Endothelial cells were characterized by positive immunofluorescent staining with a specific anti-human Factor VIII antibody (MBL, Nagoya, Japan). Gen eration of procoagulant activity in endothelial cells was determined by the method of Colucci et al. (4), with minor modifications. In brief, endothelial cells at a density of 1.5x 104/cm2 were cultured for 24 hr in Medium 199 supplemented with 10% fetal calf serum (FCS) in a 24-well plastic plate (Corning, U.S.A.). Then the cells were cultured in 2% FCS with or without TRK-100. After 24 hr, endotoxin was added to the cells at 0.1 dig/ml, and the cells were cultured for a further 6 hr. The cells were washed three times with phosphate-buffered saline (PBS), treated with 0.05% trypsin-0.02%
EDTA and sus pended with 0.5 ml of PBS. Procoagulant activity was determined by a one-stage clotting assay (4) after the cells were disrupted by three cycles of freezing and thawing. The clotting time was measured in duplicate with an automatic coagulation apparatus (Toa lyo Denshi, CA-100) using the following test system: 0.1 ml test sample, 0.1 ml human plasma and 0. The changes in blood and histological parameters in endotoxin-treated rats and the effects of TRK-100 are shown in Fig. 1 . The continuous infusion of endotoxin resulted in marked decreases in both platelet count and fibrinogen level. In contrast, there were an increase in FDP level and prolongation of APTT and PT in the endotoxin-treated group.
The GFD rate was 17% in the endotoxin 'treated group compared to 0% in the normal group. Oral administration of TRK-100 dose dependently prevented endotoxin-induced changes in blood parameters. At 0.1 mg/kg of TRK-100, the generation of FDP was sig nificantly prevented and glomerular fibrin deposition was suppressed by nearly 70%. The fibrin deposit was completely prevented in the endotoxin-treated rats when TRK-100 was at 0.3 mg/kg. GM partly suppressed the deposition of fibrin, but the effect was not statistically significant.
Endotoxin-induced procoagulant activity in endothelial cells was considered to be a tissue thromboplastin-like factor (TLF), because it failed to shorten the coagulation time of Factor VII-deficient plasma but did shorten the coagulation time of Factor VIII-deficient plasma (Table 1) . Endotoxin caused a dose dependent generation of TLF, and the maxi mal response was detected at 0.1 ug/ml. The generation reached a maximum 4 to 8 hr after the endotoxin addition (data not shown). There were no microscopic changes in mor phology of endothelial cells treated with endotoxin at concentrations ranging from 0.01 to 10 ug/ml for 6 hr. Pretreatment of endo thelial cells with TRK-100 resulted in sig nificant suppression of endotoxin-induced TLF generation at a maximum response of 10 n M (Table 1) . I n contrast, G M, a protease inhibitor, did not suppress it.
We reported here that TRK-100 was effective in inhibiting endotoxin-induced pro motion of blood coagulation and glomerular fibrin deposition in rats. In addition, TRK-100 suppressed TLF generation induced by endo toxin when added directly to cultured human endothelial cells. As TRK-100 is known to mimic well PG12 in the activation of platelet adenylate cyclase (8) and in the inhibition of platelet aggregation (6, 7) , the present findings suggest a protective role of PG12 in enhancement of coagulation induced byendo toxin. GM is known to be effective in pre vention of DIC (12), but there was no sig nificant improvement in blood parameters and glomerular fibrin deposit in the present experiment.
There is no evidence at the moment in dicating whether the ability of TRK-100 to decrease TLF in endothelial cells contributes to inhibition of endotoxin-induced changes in the blood and glomerulus, but particular attention has been given to the pathological roles of endothelial cells as a trigger in the onset of DIC. The cells participate in the enhancement of coagulation through a direct or other cell mediated mechanism of injuring stimuli (3, 13, 14) . Generation of tissue procoagulant factor in the injured endothelial cells might induce promotion of coagulation. So the suppressive effect of TRK-100 on TLF generation suggests the benefical role of TRK-100 in the enhancement of coagulation induced by endotoxin. The reason why TRK 100 suppressed TLF generation has remained unclear. It is speculated that the increased level of cAMP might be responsible for the suppression.
Galdal et al. (15) Another possible mechanism for how TRK 100 inhibits endotoxin induced enhancement of coagulation may involve its antiplatelet activity. Aggregated platelets would form clots on the impaired vascular walls to accelerate the development of DIC. TRK-100 has been shown to inhibit collagen induced decrease in platelet count over 5 hr when administered orally to rats at doses ranging from 0.1 to 3 mg/kg (6) . In the present experiments, TRK-100 significantly sup pressed endotoxin-induced decrease in platelet count at the similar dose range. The inhibition of platelet loss would be partly due to suppression of aggregation through the antiplatelet activity of TRK-100. TRK-100 has neither anticoagulant nor fibrinolytic activity in vitro (T. Murata et al., unpublished observation).
In conclusion, the antiplatelet activity and suppressive effect on TLF generation would be responsible for the protective effect of TRK-100 against endotoxin-induced en hancement of coagulation and glomelular fibrin deposition.
These findings suggest the beneficial role of TRK-100 in prevention of DIC.
